Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis

Sinotau Pharmaceutical Group

Status and phase: Terminated; Phase 2

Conditions: Stable Coronary Artery Disease; Diagnostic Certainty; Myocardial Perfusion Imaging

Treatments: Drug: XTR004

Study type: Interventional

Funder types: Industry

Identifiers

NCT07187895

STB-XTR004-202

Details and patient eligibility

About

Compare the diagnostic certainty of MIBI SPECT myocardial perfusion imaging (MPI) and XTR004 PET MPI.

Full description

This trial is a single-arm, single-center, open-label, self-controlled study. Patients with suspected or known stable coronary artery disease who have previously undergone coronary CTA showing 30%-80% stenosis in any coronary vessel, or mild to moderate stenosis, will be enrolled and sequentially undergo MIBI SPECT myocardial perfusion imaging (MPI) and XTR004 PET MPI. Imaging will be independently and blindly read by expert readers for both MIBI SPECT MPI and XTR004 PET MPI. The diagnostic certainty of the reading results from the two imaging modalities will then be compared.

Enrollment: 17 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1.Male or female participants aged 18 years or older.
• 2.Suspected or known stable coronary artery disease with related symptoms and stable condition, and having at least one coronary artery disease risk factor, including: hypertension, hyperlipidemia, diabetes, obesity, alcohol abuse, smoking, family history of coronary artery disease, postmenopausal status in women, or advanced age.
• 3.Underwent coronary CTA within the past 6 months showing 30%-90% stenosis, or indicating mild to moderate-to-severe stenosis.
• 4.Able to communicate effectively with the investigators, understand and comply with the clinical study requirements, voluntarily participate in the study, and provide written informed consent.

Exclusion criteria

• 1. Patients with a history of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).
• 2.Patients with a prior diagnosis of myocardial infarction, congenital heart disease, cardiomyopathy, myocarditis, or other cardiac diseases.
• 3.Patients known to have severe allergic reactions to alcohol.
• 4.Patients known to have an allergy or other contraindications to adenosine.
• 5.Patients known to be allergic to iodinated contrast agents.
• 6.Individuals with significant occupational exposure to ionizing radiation within the past 10 years (e.g., exceeding 50 mSv/year), or exposure to radioactive substances or ionizing radiation for therapeutic or research purposes.
• 7.Men and women of childbearing potential who do not plan to use effective contraception during the study and for 6 months after study completion (effective methods include sterilization, intrauterine hormonal devices, condoms, contraceptive pills/agents, abstinence, or partner vasectomy/tubal ligation).
• 8.Pregnant or lactating women.
• 9.Patients with claustrophobia, bipolar disorder, other psychiatric disorders, or poor compliance.
• 10.Patients who participated in another investigational drug clinical study within 30 days prior to enrollment or plan to do so during follow-up.
• 11.Any other condition that, in the opinion of the investigators, makes the patient unsuitable for participation.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

17 participants in 1 patient group

XTR004 MPI PET & MIBI SPECT MPI

Experimental group

Description:

Patients with suspected or known stable coronary artery disease who have previously undergone coronary CTA showing 30%-80% stenosis in any coronary vessel, or mild to moderate stenosis, will be enrolled and sequentially undergo MIBI SPECT myocardial perfusion imaging (MPI) and XTR004 PET MPI

Treatment:

Drug: XTR004